TY - JOUR
KW - Adolescent
KW - Adult
KW - Child
KW - Child, Preschool
KW - Drug Therapy, Combination
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Infant
KW - Leprostatic Agents
KW - leprosy
KW - Leprosy, Borderline
KW - Leprosy, Tuberculoid
KW - Male
KW - Middle Aged
KW - Recurrence
AU - Boerrigter G
AU - Ponnighaus J M
AU - Fine PE
AU - Wilson R J
AB - <p>An evaluation of a World Health Organization-recommended multidrug therapy (WHO/MDT) in 499 paucibacillary leprosy patients is described. Patients were followed for 48 months after completion of treatment. Overall relapse rates after treatment were found to be 6.5 per 1000 person years (95% confidence interval 3.4-11.4). There were 12 relapses. A relative lack of cell-mediated immunity, as suggested by number of lesions, clinical classification and lepromin test results, and poor compliance with the dapsone component of WHO/MDT, appeared to be associated with a marginally increased risk of relapse. Severe type 1 reactions after completion of treatment occurred in 17 (3.5%) patients, 15/17 during the first 12 months of follow-up. Overall, 12 (2.5%) patients developed new disabilities during or after WHO/MDT.</p>
BT - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association
C1 - http://www.ncbi.nlm.nih.gov/pubmed/2071983?dopt=Abstract
DA - 1991 Jun
DO - 10.1136/bmj.c3651
IS - 2
J2 - Int. J. Lepr. Other Mycobact. Dis.
LA - eng
N2 - <p>An evaluation of a World Health Organization-recommended multidrug therapy (WHO/MDT) in 499 paucibacillary leprosy patients is described. Patients were followed for 48 months after completion of treatment. Overall relapse rates after treatment were found to be 6.5 per 1000 person years (95% confidence interval 3.4-11.4). There were 12 relapses. A relative lack of cell-mediated immunity, as suggested by number of lesions, clinical classification and lepromin test results, and poor compliance with the dapsone component of WHO/MDT, appeared to be associated with a marginally increased risk of relapse. Severe type 1 reactions after completion of treatment occurred in 17 (3.5%) patients, 15/17 during the first 12 months of follow-up. Overall, 12 (2.5%) patients developed new disabilities during or after WHO/MDT.</p>
PY - 1991
SP - 255
EP - 61
T2 - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association
TI - Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
UR - http://ila.ilsl.br/pdfs/v59n2a06.pdf
VL - 59
SN - 0148-916X
ER -